Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TP53 | P04637 | 5/20 | 1.00 |
| ▸ | LMNA | P02545 | 4/20 | 1.00 |
| ▸ | PPM1B | O75688 | 4/20 | 1.00 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 1.00 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 1.00 |
| ▸ | GMNN | O75496 | 3/20 | 1.00 |
| ▸ | TFPI2 | P48307 | 3/20 | 1.00 |
| ▸ | PMP22 | Q01453 | 3/20 | 1.00 |
| ▸ | NFKB1 | P19838 | 3/20 | 1.00 |
| ▸ | THPO | P40225 | 3/20 | 1.00 |
| ▸ | RAB9A | P51151 | 3/20 | 1.00 |
| ▸ | PPP1CC | P36873 | 2/20 | 1.00 |
| ▸ | PPP5C | P53041 | 2/20 | 1.00 |
| ▸ | PPP1CA | P62136 | 2/20 | 1.00 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 1.00 |
| ▸ | CYP2D6 | P10635 | 1/20 | 1.00 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.36 |
| ▸ | TSHR | P16473 | 2/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Demethyl-Cantharidin SCHEMBL177729 | 1.00 | TP53 (1.00) | TP53LMNAPPM1BSMN1; SMN2KDM4E | |
| Demethyl-Cantharidin SCHEMBL9675442 | 1.00 | TP53 (1.00) | TP53LMNAPPM1BSMN1; SMN2KDM4E | |
| Demethyl-Cantharidin SCHEMBL3187662 | 1.00 | TP53 (1.00) | TP53LMNAPPM1BSMN1; SMN2KDM4E | |
| Demethyl-Cantharidin SCHEMBL3195020 | 1.00 | TP53 (1.00) | TP53LMNAPPM1BSMN1; SMN2KDM4E | |
| Demethyl-Cantharidin SCHEMBL19318920 | 1.00 | TP53 (1.00) | TP53LMNAPPM1BSMN1; SMN2KDM4E | |
| Demethyl-Cantharidin SCHEMBL6432892 | 1.00 | TP53 (1.00) | TP53LMNAPPM1BSMN1; SMN2KDM4E | |
| Demethyl-Cantharidin SCHEMBL9906842 | 1.00 | TP53 (1.00) | TP53LMNAPPM1BSMN1; SMN2KDM4E | |
| SCHEMBL16938608 | 0.84 | KDM4E (0.71) | TP53LMNAPPM1BSMN1; SMN2KDM4E | |
| SCHEMBL17695028 | 0.84 | KDM4E (0.71) | TP53LMNAPPM1BSMN1; SMN2KDM4E | |
| SCHEMBL12599313 | 0.74 | KDM4E (0.57) | TP53LMNAPPM1BSMN1; SMN2KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 52 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-116509841-B | Antitumor composition, liposome, preparation method and application | 湖南中医药大学 | 2024-08-13 | — | — | CN | claimed |
| CN-113563477-B | Novel coronavirus recombinant protein and human angiotensin converting enzyme-2 recombinant protein, and preparation methods and applications thereof | 上海健康医学院 | 2023-08-04 | — | — | CN | claimed |
| CN-116509841-A | Antitumor composition, liposome, preparation method and application | 湖南中医药大学 | 2023-08-01 | — | — | CN | claimed |
| CN-112999152-B | Targeting polymer micelle modified based on GEBP11, and preparation method and application thereof | 遵义医科大学附属医院 | 2023-04-07 | — | — | CN | claimed |
| CN-121154837-B | Crosslinked nano prodrug, nano self-assembled hydrogel precursor tablet prepared from crosslinked nano prodrug and application of nano self-assembled hydrogel precursor tablet | ANHUI UNIVERSITY (CN) | 2026-05-26 | — | — | CN | disclosed |
| CN-121796627-A | Norcantharidin nanoparticle encapsulated by engineering lactobacillus paracasei extracellular vesicles and application thereof | 上海市普陀区中心医院 | 2026-04-07 | — | — | CN | disclosed |
| CN-120774929-A | Low-oxygen response norcantharidin prodrug, and preparation method and application thereof | 武汉理工大学 | 2025-10-14 | — | — | CN | disclosed |
| US-20250304752-A1 | STATOR COMPOUND HAVING AN AZIDE CURED ELASTOMERIC BASE AND STATORS AND DOWNHOLE MOTORS USING THE SAME | PV FLUID PRODUCTS INC (US) | 2025-10-02 | — | — | US | disclosed |
| US-12378371-B2 | Stator compound having an azide cured elastomeric base and stators and downhole motors using the same | PV Fluid Products, Inc. (US) | 2025-08-05 | — | — | US | disclosed |
| WO-2025125890-A1 | PROTEIN PHOSPHATASE 2A (PPA2) ANTAGONISTS FOR DENGUE TREATMENT | CENTRO DE INVESTIGACIÓN Y DE ESTUDIOS AVANZADOS DEL I.P.N. (MX) | 2025-06-19 | — | — | WO | disclosed |
| WO-2025096952-A1 | SCAFFOLDS AND SCAFFOLD HOLDERS FOR TISSUE ENGINEERING | UNIVERSITY OF CONNECTICUT (US) | 2025-05-08 | — | — | WO | disclosed |
| CN-119258021-A | Norcantharidin liposome injection and preparation method and application thereof | 沈阳药科大学 | 2025-01-07 | — | — | CN | disclosed |
| CN-111253415-B | Norcantharidin carboxylic acid trifluoro benzyl ester and synthetic method and application thereof | 遵义医科大学 | 2022-08-09 | — | — | CN | disclosed |
| US-11406714-B2 | Telodendrimers and nanocarriers and methods of using same | THE RESEARCH FOUNDATION FOR THE STATE UNIVERSITY OF NEW YORK (US) | 2022-08-09 | — | — | US | disclosed |
| CN-111362962-B | Tetrafluorobenzyl norcantharidin carboxylate and synthesis method thereof | 遵义医科大学 | 2022-08-09 | — | — | CN | disclosed |
| US-20220213053-A1 | THIOPHENE DERIVATIVES AS ANTIVIRAL AGENTS | ENYO PHARMA (FR) | 2022-07-07 | — | — | US | disclosed |
| US-11279683-B2 | Thiophene derivatives as antiviral agents | ENYO PHARMA (FR) | 2022-03-22 | — | — | US | disclosed |
| CN-111265482-B | Glycyrrhetinic acid and/or folic acid ligand modified cantharidin solid lipid nanoparticle and preparation method thereof | 湖南中医药大学 | 2022-03-22 | — | — | CN | disclosed |
| CN-110437265-B | Homocamptothecin norcantharidinate derivative and regioselective synthesis method thereof | 遵义医学院 | 2022-02-18 | — | — | CN | disclosed |
| CN-110437264-B | Homocamptothecin 5, 6-dibromo norcantharidinate derivative and regioselective synthesis method thereof | 遵义医学院 | 2022-02-11 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220213053-A1 | THIOPHENE DERIVATIVES AS ANTIVIRAL AGENTS | MAVS, EIF2AK2, IRF3 | TP53 1353/4885LMNA 4815/4885PPM1B 738/4885 |
| US-11279683-B2 | Thiophene derivatives as antiviral agents | MAVS, EIF2AK2, IRF3 | TP53 2656/4885LMNA 4796/4885PPM1B 786/4885 |
| US-11406714-B2 | Telodendrimers and nanocarriers and methods of using same | TTI2, MTCL3, HTT | TP53 293/4885LMNA 1494/4885PPM1B 4782/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.